Kolexia
Barbarot Sebastien Dermatologie
Barbarot Sebastien
Dermatologie
Hôpital Hôtel-Dieu Nantes
Nantes, France
539 Activités
17 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Eczéma atopique Dermatite Eczéma Psoriasis Maladies de la peau Neurofibromatoses Neurofibromatose de type 1 Prurit Malformations

Collaborateurs

Voir plus
Aubert Helene
Aubert Helene
Hôpital Hôtel-Dieu Nantes, Nantes, France
Mazereeuw Juliette
Mazereeuw Juliette
Hôpital Larrey Toulouse, Toulouse, France
Stalder Jean Francois
Stalder Jean Francois
Hôpital Hôtel-Dieu Nantes, Nantes, France
Maruani Annabel
Maruani Annabel
Hôpital Trousseau Chambray lès Tours, Chambray-lès-Tours, France

Industries

Voir plus
Abbvie
34 collaboration(s)
Dernière en 2023
Sanofi
31 collaboration(s)
Dernière en 2023
Lilly
18 collaboration(s)
Dernière en 2023
Leo Pharma
13 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Measure Up 1: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis
Essai Clinique (Abbvie)   01 mars 2024
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2): A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis
Essai Clinique (Abbvie)   01 mars 2024
BRAVE-AA-PEDS: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Essai Clinique (Lilly)   28 février 2024
ADorable-2: A Phase 3, Multicenter, Long-Term Extension Study to Assess the Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Essai Clinique (Lilly)   28 février 2024
ADorable-1: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Essai Clinique (Lilly)   28 février 2024
MOSAÏQUE: Screening for Chromosomal Microarrangements by CGH-array in Developmental Anomalies of the Skin Suggestive of Mosaicism. National Multicentre Descriptive Study.
Essai Clinique (CHU Dijon-Bourgogne)   20 février 2024
Heads Up: A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis
Essai Clinique (Abbvie)   15 février 2024
Lebrikizumab Maintains Improvements in the Patient-Oriented Eczema Measure Through 2 Years of Treatment in Patients With Moderate-to-Severe Atopic Dermatitis
Programs and Abstracts of Papers to be Presented During Scientific Sessions: 2024 AAAAI Annual Meeting   01 février 2024
Burden of Atopic Dermatitis in Pediatric Patients: An International Cross-sectional Study.
The British journal of dermatology   04 décembre 2023
Effets des biologiques dans l’ichtyose : données d’une série internationale et revue de la littérature
Journées dermatologiques de Paris 2023   01 décembre 2023